Sequenom, the San Diego-based maker of laboratory tools and diagnostics, said today in a regulatory filing it has agreed to accept a $1 million payment from Ibis Biosciences, a unit of Abbott Laboratories, to settle a patent infringement lawsuit. As part of the deal, Sequenom (NASDAQ: [[ticker:SQNM]]) has granted Ibis a non-exclusive license to three mass spectrometry-based patents. Abbott acquired Ibis, a spinoff from Carlsbad, CA-based Isis Pharmaceuticals, for $215 million in December.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
